Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06486181 · ClinicalTrials.gov registry record · Phase 4
Second Line Endovascular Treatment in Acute DVT
A Phase 4 study, sponsored by Rush University Medical Center.
- Not yet
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT06486181 is a Phase 4 study that has not yet begun recruiting, run by Rush University Medical Center. The registered enrollment target is 100 participants.
The verdict
NCT06486181, a Phase 4 study, has not yet begun recruiting, sponsored by Rush University Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The goal of this study is to fill the paucity of second line endovascular treatment for acute deep venous thrombus (DVT) by using catheter-directed thrombolysis (CDT) and mechanical thrombectomy (MT) as adjunctive second-line treatments for acute DVT patients who show no improvement after an initial anticoagulation trial for one week. The main questions the study aims to answer are: \- Are adjunctive use of endovascular interventional treatments as second-line to DVT treatment safe and efficient? Participants will be followed with repeat US at 1 week after initial DVT to assess for response to anticoagulation treatment. If there is significant residual thrombus with minimal or no response to treatment, participants will be offered enrollment to the study in the office or inpatient setting. Enrolled participants will be randomized into control or intervention arms with 1:1 ratio. Researchers will compare follow-up Villalta and Marder scores between groups to see whether endovascular interventions are safe and efficient.
Interventions
- OTHER Thrombolysis/Thrombectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2029-04-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06486181
The ClinicalTrials.gov registry entry for NCT06486181 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thrombolysis/Thrombectomy is the first listed.
NCT06486181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06486181 about?
NCT06486181 is a clinical study titled "Second Line Endovascular Treatment in Acute DVT". The goal of this study is to fill the paucity of second line endovascular treatment for acute deep venous thrombus (DVT) by using catheter-directed thrombolysis (CDT) and mechanical thrombectomy (MT) as adjunctive second-line treatments for acute DVT patients who show no improvement after an initial...
What is the current status of trial NCT06486181?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2026-04-01. Estimated completion is 2029-04-30.
What interventions are being tested in trial NCT06486181?
The interventions under investigation include: Thrombolysis/Thrombectomy (OTHER).
Who is sponsoring clinical trial NCT06486181?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.